Small-Scale Bioreactors Market Size was valued at USD 1.7 Billion in 2022. The Small-Scale Bioreactors market industry is projected to grow from USD 1.965 Billion in 2023 to USD 6.267 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 15.60% during the forecast period (2024 - 2032). Increased adoption of single-use bioreactors in small-scale bioprocessing due to their cost-effectiveness, flexibility, and reduced risk of cross-contamination are the key market drivers that enhance market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Market CAGR for small-scale bioreactors is being driven by the rising demand for personalized medicine and biopharmaceuticals. Personalized medicine, which involves tailoring medical treatment to individual patients based on their genetic makeup, offers significant advancements in healthcare by enhancing treatment efficacy and minimizing adverse effects. Biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and cell-based therapies, represent a growing segment of the pharmaceutical industry, offering targeted therapies with high specificity and fewer side effects compared to traditional pharmaceuticals.
The shift towards personalized medicine and biopharmaceuticals necessitates a paradigm change in manufacturing processes, moving away from traditional batch production towards more flexible and agile production methods. Small-scale bioreactors, characterized by their compact size, scalability, and versatility, are ideally suited to meet the requirements of personalized medicine and biopharmaceutical production. Unlike large-scale bioreactors used in traditional pharmaceutical manufacturing, which are designed for high-volume production, small-scale bioreactors offer the flexibility to produce smaller batches of biologics tailored to individual patient needs. This adaptability is crucial for personalized medicine, where treatments are often customized based on patient-specific factors such as genetic variations and disease characteristics.
Furthermore, the development of biopharmaceuticals often involves iterative research and optimization processes, requiring small-scale bioreactors for feasibility studies, process development, and optimization. Small-scale bioreactors enable researchers and biopharmaceutical companies to conduct experiments at a fraction of the cost and time compared to large-scale production, facilitating faster innovation and time-to-market for new therapies. Additionally, small-scale bioreactors provide a platform for bioprocess intensification, allowing researchers to maximize product yields and optimize process conditions to improve efficiency and reduce production costs. This capability is particularly valuable in the biopharmaceutical industry, where cost-effectiveness and process efficiency are paramount.
Moreover, the growing trend towards decentralized manufacturing and point-of-care production further underscores the importance of small-scale bioreactors in the biopharmaceutical industry. Advances in bioprocessing technologies, coupled with the increasing availability of off-the-shelf bioreactor systems, enable biopharmaceutical companies and contract development and manufacturing organizations (CDMOs) to establish smaller-scale manufacturing facilities closer to the point of need. This decentralization of production facilitates rapid response to market demands, reduces supply chain risks, and enhances access to biopharmaceuticals in remote or underserved regions. Small-scale bioreactors play a crucial role in enabling decentralized manufacturing by providing scalable and cost-effective production solutions that can be easily deployed in various settings. Thus, driving the Small-Scale Bioreactors market revenue.
The Small-Scale Bioreactors Market segmentation, based on product, includes Reusable Bioreactors and Single-Use Bioreactors. In 2023, the reusable bioreactors segment dominated the market due to their cost-effectiveness and sustainability compared to single-use alternatives. By allowing multiple batches to be run without the need for frequent replacement, reusable bioreactors offer significant cost savings over time, making them attractive for research laboratories, academic institutions, and small-scale biopharmaceutical production facilities with limited budgets. Additionally, reusable bioreactors typically offer greater flexibility in terms of customization and scalability, allowing users to adapt their systems to specific research or production requirements without being constrained by pre-defined disposable formats.
Figure 1: Small-Scale Bioreactors Market, by Product, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The Small-Scale Bioreactors Market segmentation, based on capacity, includes 5ML-100ML, 100ML-250ML, 250ML-500ML, 500ML-1L, 1L-3L and 3L-5L. In 2023, the 1L-3L category dominated the market due to their versatility and suitability for various applications. These compact bioreactors offer sufficient volume for small-scale production, process development, and research activities while requiring less space and resources compared to larger systems. Additionally, their relatively lower cost makes them accessible to a wide range of users, including academic institutions, biotech startups, and small biopharmaceutical companies, driving their widespread adoption. Furthermore, the scalability of 1L-3L bioreactors allows users to seamlessly transition from research and development to larger-scale production, further solidifying their position as the preferred choice. Further, the 3L-5L category is the second most dominant as it offers quick system implementation, reduced infrastructure, increased size & turnaround flexibility, decreased risk of cross-contamination, and minimal maintenance requirement.
The Small-Scale Bioreactors Market segmentation, based on end user, includes Pharmaceutical & Biopharmaceutical Companies, CROs & CMOs and Academia & Research Institutes. In 2023, the CROs & CMOs category dominated the market due to their extensive expertise and infrastructure in providing specialized bioprocessing services. These organizations offer end-to-end solutions for biopharmaceutical development and manufacturing, including process development, scale-up, and production using small-scale bioreactors. Their ability to provide cost-effective and flexible manufacturing solutions, coupled with their regulatory compliance capabilities, makes them preferred partners for biopharmaceutical companies seeking to leverage small-scale bioreactors for product development and commercialization. Further, the academia and research institutes category is the fastest growing as these bioreactors are adopted for several procedures at a higher rate.
By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Small-Scale Bioreactors market area will dominate this market, owing to the increased adoption of personalized medicine, the growing demand for biopharmaceuticals and advancements in bioprocessing technologies, and the presence of numerous biotechnology and pharmaceutical companies.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: SMALL-SCALE BIOREACTORS MARKET SHARE BY REGION 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Small-Scale Bioreactors market accounts for the second-largest market share due to the increasing adoption of biopharmaceuticals and personalized medicine. Further, the German Small-Scale Bioreactors market held the largest market share, and the UK Small-Scale Bioreactors market was the fastest growing market in the European region.
The Asia-Pacific Small-Scale Bioreactors Market is expected to grow at the fastest CAGR from 2024 to 2032. This is due to the expanding adoption of biopharmaceuticals and the growing presence of biotechnology and pharmaceutical companies. Moreover, China’s Small-Scale Bioreactors market held the largest market share, and the Indian Small-Scale Bioreactors market was the fastest growing market in the Asia-Pacific region.
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Small-Scale Bioreactors market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the Small-Scale Bioreactors industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Small-Scale Bioreactors industry to benefit clients and increase the market sector. In recent years, the Small-Scale Bioreactors industry has offered some of the most significant advantages to several industries. Major players in the Small-Scale Bioreactors market, including Sartorius AG, Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Lonza Group, Eppendorf AG, Miltenyi Biotec, Getinge AB, Solaris Biotechnology Srl and Infors AG, and others, are attempting to increase market demand by investing in research and development operations.
Thermo Fisher Scientific is a global leader in serving science, headquartered in Waltham, Massachusetts, United States. Established through the merger of Thermo Electron and Fisher Scientific in 2006, the company operates across various segments, including life sciences, analytical instruments, specialty diagnostics, and laboratory products and services. Thermo Fisher Scientific provides a wide range of solutions to researchers, clinicians, and other professionals in academia, government, and industry. Its offerings include laboratory equipment, consumables, reagents, software, and services, enabling customers to advance scientific discovery, improve healthcare outcomes, and ensure the safety and quality of products. In October 2021, Thermo Fisher Scientific collaborated with 3M to enhance the process effectiveness and versatility in commercial therapeutic manufacturing by compiling HyPerforma Single-Use Bioreactor Systems of Thermo Scientific with Harvest RC Chromatographic Clarifier of 3M.
HEL Group is a leading provider of innovative laboratory tools and automation solutions for the chemical, pharmaceutical, and biotechnology industries. Established in 1987, HEL Group has gained a reputation for excellence in designing and manufacturing high-quality products that streamline research, development, and manufacturing processes. The company's product portfolio includes a wide range of laboratory equipment, such as reactors, calorimeters, synthesis modules, and automation systems, designed to meet the diverse needs of scientists and engineers in various industries. In January 2022, an international developer & manufacturer of cutting-edge laboratory tools for safety, process optimization and scale-up, HEL Group expanded its operation in India to strengthen the focus on the biotech industries’ rapid development.
August 2023: Sartorious collaborated with Repligen to launch an advanced bioreactor system incorporating Repligen XCell ATF upstream intensification technology into the Biostat STR bioreactor of Sartorious. This collaboration focuses on simplifying seed train and N perfusion implementation for biopharmaceutical manufacturers.
April 2023: X-platform bioreactors were launched by Cytiva to simplify single-use upstream bioprocessing operations. These bioreactors are equipped with Figurate automation solution software. It provides a range of benefits that can assist in increasing process efficiency by enhancing ergonomics, production capability and simplifying supply chain operations.
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 1.7 Billion |
| Market Size 2023 | USD 1.965 Billion |
| Market Size 2032 | USD 6.267 Billion |
| Compound Annual Growth Rate (CAGR) | 15.60% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019-2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product, Capacity, End User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Sartorius AG, Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Lonza Group, Eppendorf AG, Miltenyi Biotec, Getinge AB, Solaris Biotechnology Srl and Infors AG |
| Key Market Opportunities | · Potential to facilitate decentralized manufacturing and point-of-care production. |
| Key Market Dynamics | · Increasing demand for flexible and cost-effective bioprocessing solutions to support personalized medicine and decentralized manufacturing initiatives. |
Frequently Asked Questions (FAQ) :
The Small-Scale Bioreactors Market size was valued at USD 1.965 Billion in 2023.
The global market is projected to grow at a CAGR of 15.60% during the forecast period, 2024-2032.
North America had the largest share in the global market
The key players in the market are Sartorius AG, Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Lonza Group, Eppendorf AG, Miltenyi Biotec, Getinge AB, Solaris Biotechnology Srl and Infors AG.
The reusable bioreactor category dominated the market in 2023.
The 1L-3L had the largest share in the global market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
